Artificial intelligence (AI) and real-world evidence (RWE) are converging to accelerate the development of treatments for rare diseases. Traditional clinical trials are often impractical for these conditions due to small patient populations and the difficulty in gathering sufficient data. By integrating AI with RWE sources like EHRs, patient registries, and insurance claims, researchers can more effectively define patient cohorts, adjust for confounding factors, detect treatment patterns, and identify adverse events. Regulatory bodies like the FDA are increasingly acknowledging this hybrid approach to evidence generation. AI
IMPACT Accelerates drug discovery and regulatory approval for rare diseases by improving evidence generation.
RANK_REASON The article discusses a novel application of AI and RWE in medical research and regulatory processes, particularly for rare diseases. [lever_c_demoted from research: ic=1 ai=1.0]
- Ehrs
- Insurance Claims Auditing and Professional Services
- Life Sciences
- Patient registries
- randomized controlled trial
- real-world evidence
- United States
- United States Food and Drug Administration
- wearable technology
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
